荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 09-25 16:08:14

72.900

+0.000

0.00%

最高73.300	最低70.900	成交量38.35万
今开72.900	昨收72.900	日振幅3.29%
总市值410.87亿	流通市值152.06亿	总股本5.64亿
成交额2,773万	换手率0.18%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":72.9,"timestamp":1790323694006,"preClose":72.9,"halted":0,"volume":383500,"delay":0,"changeRate":0,"floatShares":208581239,"shares":563608243,"eps":1.5043608768971333,"marketStatus":"休市中","change":0,"latestTime":"09-25 16:08:14","open":72.9,"high":73.3,"low":70.9,"amount":27731975,"amplitude":0.032922,"askPrice":72.9,"askSize":1500,"bidPrice":72.8,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":12.112360434166044,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":72.9,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.12468885497403816,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":116.28,"timestamp":1790233200000,"preClose":124.75,"halted":0,"volume":7147200,"delay":0,"premium":"-46.24"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2669463901","title":"9月24日荣昌生物跌6.79%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463901","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463901?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:38","pubTimestamp":1790239117,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日荣昌生物跌6.79%，收盘报116.28元，换手率2.01%，成交量7.15万手，成交额8.48亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共122家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","BK1161","688331","LU1064130708.USD","LU2328871848.SGD","09995","BK1574","LU1064131003.USD","BK0239","LU2148510915.USD","BK1583","LU1969619763.USD","160916"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU0516423174.USD","LU1770034418.SGD","SG9999014674.SGD","LU2328871848.SGD","SG9999002463.SGD","LU0348825331.USD","LU1880383366.USD","688428","LU0456846285.SGD","LU0540923850.HKD","02162","01548","03347","BK1515","LU0348766576.USD","02269","LU1242518931.SGD","LU0348783233.USD","LU1303224171.USD","06990","BK1141","01877","BK1583","KURE","LU1242518857.USD","LU2399975544.HKD","LU2039709279.SGD","LU0828237510.HKD","09995","399441","BK4581","161726","LU0140636845.USD","06160","09926","SG9999002562.SGD","02696","XBI","09969","BK1576","LU0516422366.SGD","LU1961090484.USD","LU0561508036.HKD","HK0000306701.USD","LU0856984785.SGD","LU3063872942.SGD","02268","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149774004","title":"异动解读｜荣昌生物盘中下跌5.08%，生物科技板块整体承压叠加业绩持续性存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1149774004","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149774004?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:36","pubTimestamp":1790213770,"startTime":"0","endTime":"0","summary":"9月24日，荣昌生物盘中下跌5.08%，报74.6港元，成交额3159.39万港元。生物科技板块整体走弱，康方生物跌2.67%、信达生物跌1.84%、劲方医药-B跌2.72%，行业个股普遍承压。消息面上，公司上半年营收58.53亿元、净利润46.62亿元虽实现扭亏为盈，但市场持续消化其盈利结构隐忧。此外，执行董事王玉晓于8月底连续减持合计约2万股H股，亦对市场情绪形成压制。分析师预测下一年度收入及利润将大幅回落，反映市场对高增长可持续性的审慎态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"荣昌生物盘中承压，盈利结构引担忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","LU0315179316.USD","LU0348766576.USD","LU0516423091.SGD","01093","LU2476274720.SGD","02616","LU1226287792.SGD","LU1251922891.USD","02142","06978","LU1770034418.SGD","LU0039217434.USD","BK1515","LU1719994722.HKD","09926","MEDX","LU0348784397.USD","LU0417516902.SGD","SG9999002562.SGD","06185","LU0314109678.HKD","159992","HK0000165453.HKD","KCE","LU1226288253.USD","LU2039709279.SGD","LU0320764599.SGD","02269","600109","LU0708995583.HKD","09688","LU0029874061.USD","01177","LU1993786604.SGD","LU0128526141.USD","06160","LU0828237510.HKD","01801","09995","LU0359202008.SGD","LU2097828805.USD","LU1152091754.HKD","LU3063872942.SGD","01877","IBBQ","LU0348735423.USD","IE00B5MMRT66.SGD","KURE","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145747234","title":"荣昌生物2026年中期营收58.50亿元，经调整净利润46.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145747234","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145747234?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:39","pubTimestamp":1790152765,"startTime":"0","endTime":"0","summary":"荣昌生物公布2026年中期成绩。期内实现营收58.50亿元，较上年同期的10.92亿元增长约436%。同期经调整净利润为46.62亿元，上年同期对应金额为亏损，现已成功扭亏为盈。经营活动净现金流为42.14亿元，上年同期则为净流出。毛利率方面，本期毛利为55.81亿元，对应毛利率约95.41%。研发投入4.14亿元，占营收比重约7.08%，相比上年同期的6.47亿元下降约36%。销售及分销开支5.50亿元，同比上升约4.5%，占营收比重约9.40%；行政开支2.62亿元，同比提升约70.0%，占营收比重约4.48%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"荣昌生物2026年中期营收58.50亿元，经调整净利润46.62亿元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00241","09606","06618","06996","09966","06978","02137","02359","09995","02268","01801","09688","01672","03347","06606","02269","06622","03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669615960","title":"9月21日荣昌生物涨8.85%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669615960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669615960?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980142,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日荣昌生物涨8.85%，收盘报125.0元，换手率3.02%，成交量10.74万手，成交额13.19亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共122家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1583","BK0239","BK1161","LU1064130708.USD","688331","LU1064131003.USD","LU2488822045.USD","LU1969619763.USD","09995","BK1574","LU2328871848.SGD","160916"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669607159","title":"荣昌生物涨8.85%，东海证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669607159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669607159?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980130,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨8.85%，收盘报125.0元。2026年9月4日，东海证券研究员杜永宏发布了对荣昌生物的研报《公司简评报告：业绩亮眼，研发国际化加速推进》，该研报对荣昌生物给出“买入”评级。公司核心产品持续放量，研发国际化快速推进，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国泰海通的廖博闻、余文心、余克清。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","03347","06990","02696","09926","01548","01877","09995","02359","09969","02162","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","06160","LU0326950275.SGD","LU0540923850.HKD","LU0561508036.HKD","LU1961090484.USD","LU0128522744.USD","LU0348767384.USD","HK0000165453.HKD","02269","02696","02359","LU0052750758.USD","01877","LU0456827905.SGD","02162","LU0348766576.USD","BK1610","KURE","399441","LU2488822045.USD","BK1515","LU1880383366.USD","06990","161726","LU2045819591.USD","LU2476274720.SGD","LU2242644610.SGD","LU0634319403.HKD","LU0516422952.EUR","09995","LU0244354667.USD","BK4588","LU0320764243.SGD","LU0327786744.USD","01548","LU1303224171.USD","LU0348784397.USD","09926","LU0463099449.HKD","LU0196878994.USD","LU0029874905.USD","LU0320764599.SGD","03347","XBI","BK1588","02268","LU1188198961.HKD","LU0979878070.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151536979","title":"异动解读｜荣昌生物盘中上涨5.35%，RC148肺癌临床数据亮相世界肺癌大会获市场关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1151536979","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151536979?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:41","pubTimestamp":1789954912,"startTime":"0","endTime":"0","summary":"9月21日，荣昌生物盘中上涨5.35%，报78.65港元，成交额6617.6万港元。多家机构随后上调目标价，其中里昂将目标价升至144.8港元，花旗升至127.7港元，均维持买入类评级。此外，公司上半年营收58.53亿元，同比增长433.11%，净利润46.62亿元实现扭亏为盈，基本面持续改善对股价形成支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物上涨，肺癌新药数据惊艳亮相","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906290","title":"每周股票复盘：荣昌生物（688331）上半年营收增433.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906290","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906290?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:24","pubTimestamp":1789838654,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，荣昌生物报收于114.84元，较上周的114.72元上涨0.1%。本周，荣昌生物9月14日盘中最高价报119.3元。本周关注点来自业绩披露要点：2026年上半年公司总营业收入58.53亿元，同比增长433.11%。答：2026年上半年,公司的核心产品销售收入持续放量,实现销售收入13.4亿元,同比增长22.3%;总营业收入58.53亿元,同比增长433.11%。截至2026年6月30日,累计获得发明专利授权187项,实用新型专利授权37项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919551","title":"荣昌生物：9月16日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919551?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:06","pubTimestamp":1789697204,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月17日荣昌生物发布公告称公司于2026年9月16日召开业绩说明会。荣昌生物2026年中报显示，上半年度公司主营收入58.53亿元，同比上升433.11%；归母净利润46.62亿元，同比上升1137.06%；扣非净利润43.38亿元，同比上升1073.78%；其中2026年第二季度，公司单季度主营收入51.97亿元，同比上升808.6%；单季度归母净利润43.34亿元，同比上升2317.88%；单季度扣非净利润43.73亿元，同比上升2360.61%；负债率15.57%，投资收益128.7万元，财务费用2449.79万元，毛利率95.71%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800008974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1574","09995","LU1064131003.USD","688331","LU2328871848.SGD","LU2488822045.USD","BK1583","BK0239","BK1161","LU1969619763.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668959205","title":"康方生物迎大敌：荣昌生物RC148亮相世界肺癌大会 预计峰值销售额约36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959205","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668959205?lang=zh_cn&edition=full","pubTime":"2026-09-17 14:17","pubTimestamp":1789625820,"startTime":"0","endTime":"0","summary":"9月15日，荣昌生物与艾伯维联合开发的PD-1/VEGF双抗RC148一线治疗鳞状和非鳞状非小细胞肺癌的II期临床数据以口头报告形式在世界肺癌大会亮相。基于以上参数计算，RC148 大中华区峰值年销售额约为 36 亿元。从时间维度来看，RC148 预计 2030 年左右获批上市，通常创新药上市后需经历 5-7 年的市场爬坡期达到销售峰值，预计 2036 年左右达到峰值销售额，距离当前时点约 10 年。结合 0.50 的临床成功概率，最终 RC148 大中华区管线的风险调整净现值约为 5.6 亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-17/doc-iniscksf0292708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0561508036.HKD","LU0348784397.USD","09926","IE00B5MMRT66.SGD","LU0348766576.USD","LU0417516738.SGD","LU1794554557.SGD","LU0540923850.HKD","LU0348735423.USD","LU0417516571.SGD","LU2399975544.HKD","LU2778985437.USD","BK1574","LU0348827113.USD","LU0417516902.SGD","LU2328871848.SGD","LU2488822045.USD","LU0634319403.HKD","LU1720050803.USD","LU0348783233.USD","LU1961090484.USD","LU1969619763.USD","LU2148510915.USD","LU0348825331.USD","LU1064130708.USD","BK1583","LU2476274720.SGD","LU1064131003.USD","LU2476274308.USD","BK0239","KURE","BK1161","688331","09995","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680466","title":"股市必读：荣昌生物新发布《H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680466?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:17","pubTimestamp":1789323429,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，荣昌生物报收于114.72元，上涨0.57%，换手率1.39%，成交量4.94万手，成交额5.55亿元。公司公告汇总H股公告荣昌生物制药（烟台）股份有限公司于2026年9月11日通过上海证券交易所集中竞价交易方式回购A股19,000股，每股价格介于113.2元至113.7元之间，总支付金额2,155,248元；本次回购股份拟用于员工股权激励计划，未在回购实施完成公告后3年内使用的部分将予以注销；回购后库存股数量增至254,184股，已发行股份总数不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2488822045.USD","LU2328871848.SGD","LU1969619763.USD","09995","LU2148510915.USD","BK1583","BK0239","LU1064130708.USD","LU1064131003.USD","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667050720","title":"每周股票复盘：荣昌生物（688331）上半年净利46.6亿扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2667050720","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667050720?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:34","pubTimestamp":1789238050,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，荣昌生物报收于114.72元，较上周的124.24元下跌7.66%。本周，荣昌生物9月8日盘中最高价报124.22元。本周关注点来自机构调研要点：2026年上半年净利润为46.6亿元，同比实现扭亏为盈。研发费用为4.1亿元，同比下降36%，主因海外临床试验开支减少。公司已于2026年8月25日披露半年报。2026年9月11日，公司通过集中竞价交易方式购回19,000股A股，每股价格113.2元至113.7元，总支付金额2,155,248元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","LU1969619763.USD","LU1064130708.USD","09995","BK1161","LU2488822045.USD","BK1574","LU1064131003.USD","BK0239","LU2328871848.SGD","LU2148510915.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100786311","title":"荣昌生物回购1.90万股，涉资约215.52万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1100786311","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100786311?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:13","pubTimestamp":1789117987,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司（股票代码：09995）于2026年9月11日披露翌日披露报表，宣布通过上海证券交易所集中竞价方式回购A股，用于员工股权激励计划或股权激励。\n本次回购股份数量为1.90万股，占回购前公司已发行股份（不含库藏股）总数约0.005%，每股回购价格介于人民币113.20元至113.70元之间，合计动用资金人民币约215.52万元。回购完成后，公司已发行股份总数为355,642,060股，库藏股数量增至254,184股。\n公司确认已遵守香港联合交易所有限公司证券上市规则及其他相关法律法规的规定。本公告由公司董事王威东签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"荣昌生物回购1.90万股，涉资约215.52万元人民币","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666406725","title":"荣昌生物(09995.HK)9月11日斥资215.52万元回购1.9万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666406725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666406725?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:06","pubTimestamp":1789117581,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["82846","BK1161","BK1147","02846","83130","BK1583","LU1969619763.USD","07233","03130","LU2328871848.SGD","83188","BK1574","03188","02827","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股异动 | 创新药概念股持续调整 海外利率预期反复 2026国谈收官进入结果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666510786?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0244354667.USD","LU1188198961.HKD","LU0501845795.SGD","LNGR","BK1589","IE00B5MMRT66.SGD","LU0072913022.USD","KCAI","IE00BZ08YS42.EUR","06978","01093","LU0067412154.USD","LU2097828805.USD","IBBQ","MEDX","LU1831875114.USD","BK1161","PEVC","02157","IE00BZ08YT58.USD","VXUS","LU0326950275.SGD","BK1191","LU0455707207.USD","LU1226288170.HKD","LU1008478684.HKD","LU1813983027.USD","LU1328277881.USD","LU2097828474.EUR","LU1226287875.USD","LU2488822045.USD","09995","MCRO","IE0008368742.USD","LU1226287792.SGD","LU2242644610.SGD","WRTH","BK1515","LU1969619763.USD","LU2328871848.SGD","KURE","LU0880133367.SGD","01801","LU1807302812.USD","BK4585","159992","LU1960683339.HKD","LU0149534421.HKD","IE0008369823.USD","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666128556","title":"【券商聚焦】中信证券：中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666128556","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666128556?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:59","pubTimestamp":1789001960,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年以来，中国创新药国内市场快速放量，从中报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；出海创新药开始进入三期/注册研究兑现阶段；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。该机构认为中国创新药进入全球价值兑现阶段，建议关注：①头部国际化创新药企业有望迎来产品全球价值兑现期；②头部创新药企业产品放量进入新的成长阶段；③具有全球潜力的管线资产国际化有望加速兑现。综上，我们维持创新药行业“强于大市”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991210","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU1064130708.USD","LU0572944931.SGD","KURE","LU2039709279.SGD","BK0028","IE0008369823.USD","LU1655091616.SGD","02142","06030","LU1720050803.USD","06160","LU0405327494.USD","LU0561508036.HKD","LU0979878070.USD","LU0181495838.USD","06185","LU1997245177.USD","LU1580142542.USD","LU1794554557.SGD","LU1961090484.USD","SG9999004220.SGD","LU2148510915.USD","LU0348825331.USD","IE00B543WZ88.USD","LU2580892862.HKD","LU1226287792.SGD","LU1880383366.USD","LU0463099449.HKD","KCE","BK1161","09995","LU0417516738.SGD","01177","LU0348783233.USD","LU1226287875.USD","LU1820825898.SGD","LU1255011170.USD","01093","09926","LU0516422952.EUR","LU1813983027.USD","LU1969619763.USD","02269","02616","BK1141","01877","600030","LU0819121731.USD","09688"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0933},{"period":"3month","weight":0.0467},{"period":"6month","weight":-0.2257},{"period":"1year","weight":-0.3187},{"period":"ytd","weight":0.0125}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.049233},{"month":6,"riseRate":0.666667,"avgChangeRate":0.089626},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.010221},{"month":8,"riseRate":0.333333,"avgChangeRate":0.055035},{"month":9,"riseRate":0.5,"avgChangeRate":0.066576},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}